Revvity (RVTY)
NYSEHealth CareMedical - Diagnostics & ResearchSnapshot 2026-11-04
$159.43-2.48%
Close 2026-11-04 · 1-day change
NYSEHealth CareMedical - Diagnostics & ResearchSnapshot 2026-11-04
QuarterlyIQ Insights · RVTY
What must go right, what could break, what the price assumes, and what evidence comes next.
The current health of the standing investment case.
Recent financial performance is holding in the top half of its industry — the reason to own it looks intact.
One-year growth currently built into the price, compared with our model's estimate.
| Measure | Marker shape | Value |
|---|---|---|
| Growth built into the price | circle | 15.6% |
| Our one-year growth estimate | diamond | 3.3% |
For each item: what to watch, what would become a concern, and what would make it less concerning.
A reporting-risk estimate, not a forecast of the stock-price response.
Historical relationships that met the evidence threshold. They do not prove cause or forecast a move.
Usually moved in the same direction.
Price observations: 365 days
Most sensitive to the broad stock market.
Based on historical daily prices through 2026-11-04.
Past price behavior in dollars on a $10,000 position. This does not measure permanent business risk.
How much price usually moves either way.
A larger daily loss that occurred about once in every 20 trading days.
Use the underlying financial and sector pages to investigate the cause.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Growth built into the price is above our model estimate.
The price assumes 12.3 percentage points more one-year growth.
The one-year revenue growth assumption on Valuation.
Model as of 2026-11-04 · Compared with 12 industry peers · Company calendar date is not available
RVTY — divestiture
Dated 2026-11-03
Other Events Exhibit 99.2 to the Current Report on Form 8-K sets forth the unaudited pro forma condensed consolidated financial statements to present the pro forma financial position and results of operations of the Company and its Subsidiaries based upon historical financial information after giving effect to the probable sale of substantially all of the assets related to the Company’s Immunodiagnostics business in China (“China IDX”) pursuant to a definitive agreement signed on July 31, 202…
Why it matters: Revvity raised its 2026 profit range after Q2. Full-year results will test whether that increase holds.
Supportive ifManagement keeps 2026 pro forma adjusted EPS guidance at $5.30-$5.40, and full-year EPS lands within that range.
Worry ifManagement cuts the range below $5.30, or full-year pro forma adjusted EPS falls below $5.30.
Why it matters: China IDX made up about 6% of 2025 revenue. Closing the sale would finish a key portfolio change.
Watch forRevvity says the China IDX sale closed by the end of 2027, after needed approvals.
Also watch forThe sale fails to get required approval, or remains open after year-end 2027.
Why it matters: Diagnostics pro forma organic revenue grew 11% in Q2. Keeping strong growth would support the company-wide target.
Supportive ifDiagnostics pro forma organic revenue growth stays above 8% year over year in Q3.
Worry ifDiagnostics pro forma organic revenue growth falls to 8% or less year over year in Q3.
Why it matters: Life Sciences pro forma organic revenue fell 3% in Q2. Growth here would ease the drag on company sales.
Supportive ifLife Sciences pro forma organic revenue grows year over year in Q3 or Q4.
Worry ifLife Sciences pro forma organic revenue falls at least 3% year over year again in Q3 or Q4.
Deepest peak-to-trough drop in the last year.
| Measure | Value | Meaning |
|---|---|---|
| Typical day | ±$133 on $10,000 · ±1.3% | How much price usually moves either way. |
| Bad day | $352 loss on $10,000 · 3.5% | A larger daily loss that occurred about once in every 20 trading days. |
| Largest peak-to-trough drop in the past year | $3,009 loss on $10,000 · 30.1% | Deepest peak-to-trough drop in the last year. |
Past year. 1.00 means similar movement; 1.20 means about 20% more.
Past year. 1.00 means similar movement to the sector. This is secondary context.
Latest 30 trading days, shown as an annual percentage.
Latest 252 trading days, shown as an annual percentage.
20-trading-day average in US dollars.
Trading days used by the source risk snapshot.
Past results, not a forecast. Not investment advice.
Why it matters: Q2 growth was 3%, and the 2026 goal is 4% to 5%. A higher Q3 rate would support that goal.
Supportive ifQ3 pro forma organic revenue growth is above 3% year over year, and 2026 guidance stays at 4% to 5%.
Worry ifQ3 pro forma organic revenue growth is below 3%. Or management cuts 2026 growth guidance below 4%.